By Spondylitis Association of America
On October 20th, 2017 Janssen Biotech, Inc. announced that the FDA has approved SIMPONI ARIA (IV administered golimumab) for the treatment of adults with active ankylosing spondylitis (AS) or active psoriatic arthritis (PsA.)
One of the larger challenges involved in treating ankylosing spondylitis (AS) is the varying effects of, and responses to, available medications. Currently, Tumor Necrosis Factors (TNF) inhibitors are the standard of care for most patients with moderate to severe AS, and, as with any form of organic medication, their effectiveness can be influenced by various biological factors.
VAN NUYS, CA (September 19, 2017) – The Board of Directors of the Spondylitis Association of America (SAA) has announced that it has selected Cassie Shafer as the new Chief Executive Officer/Executive Director, effective Sept. 18, 2017.
Have you ever met a doctor who was uninformed about spondylitis?
Far too many people have. The average spondylitis patient will wait almost...
By OHSU Internal Review Board
The following is an announcement from SAA about a third party study. SAA is not affiliated with this study.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.